Coplan J D, Pine D, Papp L, Martinez J, Cooper T, Rosenblum L A, Gorman J M
College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Neuropsychopharmacology. 1995 Aug;13(1):65-73. doi: 10.1016/0893-133X(95)00018-9.
In this paper the authors examine the interrelationship of both the noradrenergic (NA) system and the hypothalamic-pituitary-adrenal (HPA) axis and its implications for panic disorder (PD). Seventeen PD patients and 16 healthy volunteers were challenged orally 12 weeks apart with the alpha 2-agonist clonidine (13 healthy volunteers and 12 patients repeated the challenge). Between challenges, PD patients were treated with fluoxetine, with 10 of 12 improving at least moderately. Both during the acute phase of the illness and during the phase of pharmacological improvement, patients demonstrated a greater percentage of reductions of plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and plasma cortisol during clonidine challenge. We used correlational matrices to examine the relationship between the NA system, as reflected by plasma MHPG, and the HPA axis, as reflected by plasma cortisol measures. Healthy volunteers exhibited multiple significant "couplings" between either baseline or maximal decrease (delta max) of plasma MHPG, with either baseline or delta max plasma cortisol measures both within the first and second challenges and between the first and second challenges. In contrast, PD patients demonstrated "uncoupling" of the NA system and the HPA axis, with no significant correlations observed between either baseline and/or maximal decrease (delta max) measures of MHPG with the same cortisol measures for either the first or second challenge. The same uncoupling was observed for NA/HPA correlations between the first and second challenges. These data suggest that the hyperresponsivity to clonidine in PD patients persists during fluoxetine treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
在本文中,作者研究了去甲肾上腺素能(NA)系统与下丘脑 - 垂体 - 肾上腺(HPA)轴之间的相互关系及其对惊恐障碍(PD)的影响。17名PD患者和16名健康志愿者在相隔12周的时间里口服α2激动剂可乐定进行激发试验(13名健康志愿者和12名患者重复了该激发试验)。在两次激发试验期间,PD患者接受氟西汀治疗,12名患者中有10名至少有中度改善。在疾病急性期和药物改善期,患者在可乐定激发试验期间血浆3 - 甲氧基 - 4 - 羟基苯乙二醇(MHPG)和血浆皮质醇的降低百分比更大。我们使用相关矩阵来研究由血浆MHPG反映的NA系统与由血浆皮质醇测量反映的HPA轴之间的关系。健康志愿者在第一次和第二次激发试验期间以及第一次和第二次激发试验之间,血浆MHPG的基线或最大降幅(δ最大值)与血浆皮质醇的基线或δ最大值之间表现出多个显著的“耦合”。相比之下,PD患者表现出NA系统与HPA轴的“解耦”,在第一次或第二次激发试验中,MHPG的基线和/或最大降幅(δ最大值)测量值与相同的皮质醇测量值之间未观察到显著相关性。在第一次和第二次激发试验之间的NA/HPA相关性方面也观察到了同样的解耦现象。这些数据表明,PD患者对可乐定的高反应性在氟西汀治疗期间持续存在。(摘要截短至250字)